Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
November 13 2015 - 4:05PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that
it has priced an offering of €425 million aggregate principal
amount of 1.50% senior notes due 2020 at an issue price of 99.971%
of the principal amount. The issuance of the notes is expected to
close on or about November 24, 2015, subject to customary closing
conditions. The notes will pay interest on an annual basis.
The company plans to use a portion of the net proceeds of the
offering to redeem all of the outstanding $400 million aggregate
principal amount of 3.50% senior notes issued by Life Technologies
Corporation prior to its acquisition by Thermo Fisher, which mature
on January 15, 2016, and the remainder for general corporate
purposes.
The joint book-running managers for the offering are Deutsche
Bank AG, London Branch and HSBC Bank plc.
The offering is being made pursuant to an effective registration
statement on Form S-3 (including a prospectus) filed with the U.S.
Securities and Exchange Commission (“SEC”). Prospective investors
should read the prospectus forming a part of that registration
statement and the prospectus supplement related to the offering and
the other documents that the company has filed with the SEC for
more complete information about the company and this offering.
These documents are available at no charge by visiting EDGAR on the
SEC website at www.sec.gov. Alternatively, Thermo Fisher, the
underwriters or any dealer participating in this offering will
arrange to send you the prospectus if you request it by calling
Deutsche Bank AG, London Branch toll-free at 1-800-503-4611, or by
calling HSBC Bank plc toll-free at 1-866-811-8049.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about the company’s
intended use of proceeds. These statements involve a number of
risks and uncertainties that could cause actual results to differ
materially from currently anticipated results, including risks and
uncertainties relating to capital markets conditions and completion
of the offering. Additional important factors and information
regarding Thermo Fisher’s business that could cause actual results
to differ materially from those indicated by such forward-looking
statements are set forth in the prospectus and prospectus
supplement dated November 13, 2015 related to the offering, which
is on file with the SEC and available in the “Investors” section of
our website under the heading “SEC Filings,” and the documents
incorporated by reference into the prospectus and prospectus
supplement. While we may elect to update forward-looking statements
at some point in the future, we specifically disclaim any
obligation to do so, even if circumstances change and, therefore,
you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151113005814/en/
Thermo Fisher Scientific Inc.Media Contact Information:Ron
O’Brien, 781-622-1242ron.obrien@thermofisher.comorInvestor Contact
Information:Ken Apicerno,
781-622-1294ken.apicerno@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Apr 2023 to Apr 2024